FDA
-
-
-
-
-
-
-
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
-
-
-
-
-
-
-
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
-
-
-
-
-
-
-
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide
-
-
-
-
-
-
-
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
-
-
-
-
-
-
-
FDA Commissioner Marty Makary to step down - Politico
-
-
-
-
-
-
-
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
-
-
-
-
-
-
-
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
-
324,250 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
